Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Goodwill & Intangibles (2016 - 2026)

United Therapeutics' Goodwill & Intangibles history spans 16 years, with the latest figure at $116.5 million for Q4 2025.

  • On a quarterly basis, Goodwill & Intangibles rose 4.11% to $116.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $116.5 million, a 4.11% increase, with the full-year FY2025 number at $116.5 million, up 4.11% from a year prior.
  • Goodwill & Intangibles hit $116.5 million in Q4 2025 for United Therapeutics, roughly flat from $116.7 million in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for UTHR hit a ceiling of $116.7 million in Q3 2025 and a floor of $44.4 million in Q3 2023.
  • Historically, Goodwill & Intangibles has averaged $75.8 million across 5 years, with a median of $44.7 million in 2021.
  • Biggest five-year swings in Goodwill & Intangibles: tumbled 71.79% in 2021 and later skyrocketed 159.33% in 2024.
  • Tracing UTHR's Goodwill & Intangibles over 5 years: stood at $44.6 million in 2021, then decreased by 0.22% to $44.5 million in 2022, then surged by 156.63% to $114.2 million in 2023, then fell by 2.01% to $111.9 million in 2024, then rose by 4.11% to $116.5 million in 2025.
  • Business Quant data shows Goodwill & Intangibles for UTHR at $116.5 million in Q4 2025, $116.7 million in Q3 2025, and $111.5 million in Q2 2025.